Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Lifetime costs of invasive meningococcal disease: a Markov model approach
Author: Wang, B.
Hajiali Afzali, H.
Giles, L.
Marshall, H.
Citation: Vaccine, 2019; 37(46):6885-6893
Publisher: Elsevier
Issue Date: 2019
ISSN: 0264-410X
Statement of
Bing Wang, Hossein Haji Ali Afzali, Lynne Giles, Helen Marshall
Abstract: Introduction: Invasive meningococcal disease (IMD) is an uncommon but life-threatening infectious disease associated with high sequelae rates in young children and an increased risk of mortality in adolescents and young adults. Funding decisions to reject inclusion of new meningococcal serogroup B vaccines on national immunisation schedules have been criticised by IMD patients, their families, paediatricians and charity organisations. We aim to estimate the lifetime costs of IMD with the best available evidence to inform cost-effectiveness analyses. Methods: A Markov model was developed taking healthcare system and societal perspectives. A range of data including age-specific mortality rates, and probabilities of IMD-related sequelae were derived from a systematic review and meta-analysis. All currencies were inflated to year 2017 prices by using consumer price indexes in local countries and converted to US dollars by applying purchasing power parities conversion rates. Expert panels were used to inform the model development process including key structural choices and model validations. Results: The estimated lifetime societal cost is US$319,896.74 per IMD case including the direct healthcare cost of US$65,035.49. Using a discount rate of 5%, the costs are US$54,278.51 and US$13,968.40 respectively. Chronic renal failure and limb amputation result in the highest direct healthcare costs per patient. Patients aged < 5 years incur the higher healthcare expenditure compared with other age groups. The costing results are sensitive to the discount rate, disease incidence, acute admission costs, and sequelae rates and costs of brain injuries and epilepsy. Conclusions: IMD can result in substantial costs to the healthcare system and society. Understanding the costs of care can assist decision-making bodies in evaluating cost-effectiveness of new vaccine programs.
Keywords: Meningococcal disease; costs; Markov model
Rights: © 2019 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.vaccine.2019.09.060
Grant ID:
Published version:
Appears in Collections:Aurora harvest 4
Public Health publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.